Devarakonda, Siddhartha
Govindan, Ramaswamy
Article History
Received: 14 May 2019
Accepted: 6 June 2019
First Online: 5 July 2019
Competing interests
: S.D. serves on the steering committee for Guardant 360 but does not accept financial compensation. R.G. has received honoraria for consulting from AbbVie, Genentech, Janssen, AstraZeneca, EMD Sereno, BMS, Pfizer, Nektar, Merck, Celgene, and GSK. RG’s work is supported in part by an NCI grant (U54CA224083 Washington University PDX Development and Trial Center). S.D. and R.G. are principal investigators on industry sponsored clinical trials for which their institution receives funding and research support.